Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965288 | 0.91 | PPARA (0.54) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL5721848 | 0.91 | PPARA (0.54) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3963024 | 0.87 | TRPM8 (0.67) | TRPM8NPC1RAB9APPARAPPARG | |
| SCHEMBL3968262 | 0.85 | TRPM8 (0.51) | TRPM8TP53MAPTNPC1RAB9A | |
| SCHEMBL5364382 | 0.85 | TRPM8 (0.51) | TRPM8TP53MAPTNPC1RAB9A | |
| SCHEMBL3961870 | 0.82 | TRPM8 (0.47) | TRPM8TP53MAPTNPC1RAB9A | |
| SCHEMBL3963635 | 0.82 | TRPM8 (0.54) | TRPM8TP53MAPTPPARA | |
| SCHEMBL3959694 | 0.81 | TRPM8 (0.51) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3963569 | 0.81 | TRPM8 (0.55) | TRPM8PPARAPPARGPPARD | |
| SCHEMBL3956930 | 0.81 | MAPT (0.41) | TRPM8TP53MAPTPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | TRPM8 4071/4885TP53 4725/4885MAPT 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.